1-7 of 7
Keywords: Eltrombopag
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow-Up of Eltrombopag Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China

Subject Area:
Hematology , Oncology
Qinglin Hu, Yuan Yang, Chen Yang, Miao Chen, Bing Han
Journal: Acta Haematologica
Acta Haematol 1–10.
https://doi.org/10.1159/000539905
Published Online: 17 July 2024
...Qinglin Hu; Yuan Yang; Chen Yang; Miao Chen; Bing Han Introduction: Aplastic anemia (AA) is characterized by bone marrow failure and cytopenia. Eltrombopag (ELT) is effective and safe for treating refractory/relapsed AA; however, reports on the long-term outcomes of transfusion-dependent non-severe...
View article titled, Long-Term Follow-Up of <span class="search-highlight">Eltrombopag</span> Treatment for Patients with Cyclosporin A Refractory&#x2F;Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China
Open the PDF for Long-Term Follow-Up of <span class="search-highlight">Eltrombopag</span> Treatment for Patients with Cyclosporin A Refractory/Relapsed Transfusion-Dependent Non-Severe Aplastic Anemia: A Report from a Single Center in China in another window
Journal Articles

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

Subject Area:
Karger e-Journal Backfile Collection 2023 , Hematology , Oncology
Moshe Mittelman, Uwe Platzbecker, Sebastian Grosicki, Tomasz Lawniczek, Zewen Zhu, Dominik Selleslag
Journal: Acta Haematologica
Acta Haematol (2023) 146 (5): 373–378.
https://doi.org/10.1159/000531146
Published Online: 19 May 2023
...Moshe Mittelman; Uwe Platzbecker; Sebastian Grosicki; Tomasz Lawniczek; Zewen Zhu; Dominik Selleslag ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome...
View article titled, Long-Term Safety and Efficacy of <span class="search-highlight">Eltrombopag</span> for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
Open the PDF for Long-Term Safety and Efficacy of <span class="search-highlight">Eltrombopag</span> for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study in another window
Journal Articles

Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel

Subject Area:
Hematology , Oncology
Nichola Cooper, Quentin A. Hill, John Grainger, John-Paul Westwood, Charlotte Bradbury, Drew Provan, Jecko Thachil, Nicholas Ramscar, Anuja Roy
Journal: Acta Haematologica
Acta Haematol (2021) 144 (4): 418–426.
https://doi.org/10.1159/000510676
Published Online: 31 March 2021
..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Eltrombopag Immune thrombocytopenia Romiplostim Thrombopoietin receptor...
View article titled, Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel
Open the PDF for Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel in another window
Journal Articles

Eltrombopag for the Treatment of Severe Inherited Thrombocytopenia

Subject Area:
Hematology , Oncology
Karim Abdelmoumen, Marc Fabre, Sophie Ducastelle-Lepretre, Remi Favier, Paola Ballerini, Jean Claude Bordet, Yesim Dargaud
Journal: Acta Haematologica
Acta Haematol (2021) 144 (3): 308–313.
https://doi.org/10.1159/000509922
Published Online: 28 September 2020
... mucocutaneous bleeds, requiring frequent platelet transfusions. Thrombocytopenia was explained by the presence of 4 mutations in 3 hematopoietic transcription factor genes: FLI1 , RUNX1 , and ETV6 . The patient was successfully treated with high-dose eltrombopag at 150 mg/day, an orally available non-peptide...
View article titled, <span class="search-highlight">Eltrombopag</span> for the Treatment of Severe Inherited Thrombocytopenia
Open the PDF for <span class="search-highlight">Eltrombopag</span> for the Treatment of Severe Inherited Thrombocytopenia in another window
Journal Articles

An Eltrombopag Red (Plasma) Alert

Subject Area:
Hematology , Oncology
Hanny Al-Samkari, Katayoon Goodarzi
Journal: Acta Haematologica
Acta Haematol (2021) 144 (2): 227–228.
https://doi.org/10.1159/000508599
Published Online: 22 July 2020
...Hanny Al-Samkari; Katayoon Goodarzi Eltrombopag is a thrombopoietin receptor agonist frequently used to manage immune thrombocytopenia and aplastic anemia. At the high doses used for aplastic anemia, but not the doses used for immune thrombocytopenia, eltrombopag can cause reddish-brown...
View article titled, An <span class="search-highlight">Eltrombopag</span> Red (Plasma) Alert
Open the PDF for An <span class="search-highlight">Eltrombopag</span> Red (Plasma) Alert in another window
Journal Articles

A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia

Subject Area:
Hematology , Oncology
Russell K. Brynes, Raymond S.M. Wong, Maung M. Thein, Kalpana K. Bakshi, Paul Burgess, Dickens Theodore, Attilio Orazi
Journal: Acta Haematologica
Acta Haematol (2017) 137 (2): 66–72.
https://doi.org/10.1159/000452992
Published Online: 01 February 2017
...Russell K. Brynes; Raymond S.M. Wong; Maung M. Thein; Kalpana K. Bakshi; Paul Burgess; Dickens Theodore; Attilio Orazi Background: The long-term effects of eltrombopag on bone marrow (BM) reticulin and/or collagen deposition in previously treated adults with chronic immune thrombocytopenia (ITP...
View article titled, A 2-Year, Longitudinal, Prospective Study of the Effects of <span class="search-highlight">Eltrombopag</span> on Bone Marrow in Patients with Chronic Immune Thrombocytopenia
Open the PDF for A 2-Year, Longitudinal, Prospective Study of the Effects of <span class="search-highlight">Eltrombopag</span> on Bone Marrow in Patients with Chronic Immune Thrombocytopenia in another window
Journal Articles

Is There a Role for Low-Dose Eltrombopag as Maintenance Therapy in the Treatment of Immune Thrombocytopenia?

Subject Area:
Hematology , Oncology
Efthymia Vlachaki, Nikolaos Sousos, Vasilios Perifanis, Georgia Kaiafa, Ilias Onoufriadis, Apostolos Hatzitolios, Panagiota Boura
Journal: Acta Haematologica
Acta Haematol (2014) 133 (1): 78–82.
https://doi.org/10.1159/000361075
Published Online: 23 August 2014
...Efthymia Vlachaki; Nikolaos Sousos; Vasilios Perifanis; Georgia Kaiafa; Ilias Onoufriadis; Apostolos Hatzitolios; Panagiota Boura Background/Aim: Thrombopoietin receptor agonists (romiplostim and eltrombopag) have recently been licensed for the treatment of thrombocytopenia in patients with chronic...
View article titled, Is There a Role for Low-Dose <span class="search-highlight">Eltrombopag</span> as Maintenance Therapy in the Treatment of Immune Thrombocytopenia?
Open the PDF for Is There a Role for Low-Dose <span class="search-highlight">Eltrombopag</span> as Maintenance Therapy in the Treatment of Immune Thrombocytopenia? in another window